| Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors M Bantscheff, D Eberhard, Y Abraham, S Bastuck, M Boesche, S Hobson, ... Nature biotechnology 25 (9), 1035-1044, 2007 | 1165 | 2007 |
| Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes M Bantscheff, C Hopf, MM Savitski, A Dittmann, P Grandi, AM Michon, ... Nature biotechnology 29 (3), 255-265, 2011 | 734 | 2011 |
| YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors P Marti, C Stein, T Blumer, Y Abraham, MT Dill, M Pikiolek, V Orsini, ... Hepatology 62 (5), 1497-1510, 2015 | 192 | 2015 |
| High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions D Hoepfner, SB Helliwell, H Sadlish, S Schuierer, I Filipuzzi, S Brachat, ... Microbiological research 169 (2-3), 107-120, 2014 | 156 | 2014 |
| A role for centrin 3 in centrosome reproduction S Middendorp, T Küntziger, Y Abraham, S Holmes, N Bordes, M Paintrand, ... The Journal of Cell Biology 148 (3), 405-416, 2000 | 134 | 2000 |
| High‐parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action HC Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Smets, J Bald, ... Cytometry Part A 95 (3), 279-289, 2019 | 114 | 2019 |
| Target of rapamycin complex 2 regulates actin polarization and endocytosis via multiple pathways D Rispal, S Eltschinger, M Stahl, S Vaga, B Bodenmiller, Y Abraham, ... Journal of Biological Chemistry 290 (24), 14963-14978, 2015 | 82 | 2015 |
| Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab T Casneuf, HC Adams III, NWCJ van de Donk, Y Abraham, J Bald, ... Leukemia 35 (2), 573-584, 2021 | 65 | 2021 |
| Multiparametric analysis of screening data: growing beyond the single dimension to infinity and beyond Y Abraham, X Zhang, CN Parker Journal of biomolecular screening 19 (5), 628-639, 2014 | 39 | 2014 |
| Jenkins-CI, an open-source continuous integration system, as a scientific data and image-processing platform IK Moutsatsos, I Hossain, C Agarinis, F Harbinski, Y Abraham, L Dobler, ... SLAS DISCOVERY: Advancing Life Sciences R&D 22 (3), 238-249, 2017 | 25 | 2017 |
| Exploring Glucocorticoid Receptor Agonists Mechanism of Action Through Mass Cytometry and Radial Visualizations Y Abraham, B Gerrits, MG Ludwig, M Rebhan, C Gubser Keller Cytometry Part B: Clinical Cytometry 92 (1), 42-56, 2017 | 18 | 2017 |
| Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector memory T … NWCJ Van de Donk, H Adams III, G Vanhoof, J Krejcik, K Van der Borght, ... Blood 130, 3124, 2017 | 15 | 2017 |
| Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas U Philippar, T Lu, N Vloemans, M Bekkers, L Van Nuffel, M Gaudiano, ... Cancer Research 80 (16_Supplement), 5690-5690, 2020 | 12 | 2020 |
| High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism … H Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Casneuf, T Smets, ... Blood 128 (22), 4521, 2016 | 11 | 2016 |
| NK cell phenotype is associated with response and resistance to daratumumab in relapsed/refractory multiple myeloma CPM Verkleij, KA Frerichs, MEC Broekmans, C Duetz, CA O’Neill, ... HemaSphere 7 (5), 2023 | 5 | 2023 |
| Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions C Agarinis, V Orsini, P Megel, Y Abraham, H Yang, C Mickanin, V Myer, ... Journal of Biomolecular Screening 21 (3), 269-276, 2016 | 3 | 2016 |
| DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS U Philippar, T Lu, N Vloemans, M Bekkers, L van Nuffel, M Gaudiano, ... Hematological Oncology 37, 128-128, 2019 | 2 | 2019 |
| Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion CPM Verkleij, KA Frerichs, C Duetz, S Zweegman, PM Homan-Weert, ... Blood 138, 728, 2021 | | 2021 |
| Understanding the anti-tumor activities of daratumumab in natural killer/T cell lymphoma (NKTCL) T Zhou, M Qing, Y Abraham, T Perova, C Sweeney, M Krevvata Cancer Research 81 (13_Supplement), 1023-1023, 2021 | | 2021 |
| Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas U Philippar, T Lu, L Fontan, N Vloemans, M Bekkers, L van Nuffel, ... Blood Cancer Discovery 1 (3_Supplement), PO-49-PO-49, 2020 | | 2020 |
Gerard DrewesCellzome/GlaxoSmithKline R&DVerified email at gsk.com
